Pfizer’s Vydura (rimegepant) has received a positive opinion from the National Institute for Health and Care Excellence (NICE) for routine NHS use as a treatment for acute migraine. This marks the first time an oral G protein-coupled receptor (GPCR) receptor antagonist has been recommended for such use. Vydura is indicated for adults with acute migraine, with or without aura, who have not found sufficient relief from previous therapies.
To be eligible, patients must have tried at least two triptan-based therapies that were either ineffective, poorly tolerated, or contraindicated. They must also have migraines that do not respond to non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. An estimated 13,000 acute migraine patients could be eligible for Vydura treatment.
This recommendation follows NICE’s prior authorization of Vydura for preventing episodic migraine attacks in May. The drug had been considered for acute use at that time but was initially rejected on cost-effectiveness grounds. Vydura has a list price of £12.90 per 75 mg tablet.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
